Read by QxMD icon Read

Breast cancer meta-analysis

Wu Ding, Zhian Li, Caiyun Wang, Jiangfeng Dai, GuoDong Ruan, Chuanjian Tu
PURPOSE: The clinical benefits provided by using anthracycline-contained regimens in patients with early breast cancer (EBC) remain uncertain. This meta-analysis used data from all relevant trials to compare treatment outcomes for patients with EBC receiving adjuvant chemotherapy with non-anthracycline-contained regimens or anthracycline-contained regimens. PATIENTS AND METHODS: Individual patient data were collected on 7 randomized trials comparing non-anthracycline-contained regimens with anthracycline-contained regimens, a total of 14,451 women were analyzed...
October 2018: Medicine (Baltimore)
Ju-Han Lee, Hoiseon Jeong, Jung-Woo Choi, Hwa Eun Oh, Young-Sik Kim
BACKGROUND: Liquid biopsies using circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) have been developed for early cancer detection and patient monitoring. To investigate the clinical usefulness of ctDNA aberrations and cfDNA levels in patients with breast cancer (BC), we conducted a meta-analysis of 69 published studies on 5736 patients with BC. METHODS: The relevant publications were identified by searching PubMed and Embase databases. The effect sizes of outcome parameters were pooled using a random-effects model...
October 2018: Medicine (Baltimore)
Joanna Picot, Neelam Kalita, Wendy Gaisford, Petra Harris, Oluchukwu Onyimadu, Keith Cooper
Clinical and cost-effectiveness evidence on fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer was submitted to the single technology appraisal process of the National Institute for Health and Care Excellence by the manufacturer of fulvestrant. The Southampton Health Technology Assessments Centre was commissioned by the National Institute for Health and Care Excellence as an independent Evidence Review Group to critique the company's submitted evidence. Fulvestrant was compared directly with anastrozole in two randomised controlled trials and was compared indirectly by means of a network meta-analysis with anastrozole, letrozole and tamoxifen...
October 17, 2018: PharmacoEconomics
Su Yon Jung, Nick Mancuso, Herbert Yu, Jeanette Papp, Eric M Sobel, Zuo-Feng Zhang
Insulin-resistance (IR)-related genetic variants are possibly associated with breast cancer, and the gene-phenotype-cancer association could be modified by lifestyle factors including obesity, physical inactivity, and high-fat diet. Using data from postmenopausal women, a population highly susceptible to obesity, IR, and increased risk of breast cancer, we implemented a genome-wide association study (GWAS) in 2 steps: 1) GWAS meta-analysis of gene-environmental (i.e., behavioral) interaction (G*E) for IR phenotypes (hyperglycemia, hyperinsulinemia, and homeostatic model assessment-insulin resistance); and 2) after the G*E GWAS meta-analysis, the identified single-nucleotide polymorphisms (SNPs) were tested for their associations with breast cancer risk in overall or subgroup population, where the SNPs were identified at genome-wide significance...
October 16, 2018: Cancer Prevention Research
Antje Wienecke, Hannelore Neuhauser, Klaus Kraywinkel, Benjamin Barnes
OBJECTIVE: In order to quantify the preventive potential of body weight reduction in Germany, population-attributable risks (PARs) were estimated for 13 cancer types. METHODS: PARs were calculated using body weight prevalence from a nationwide survey from 1998, cancer incidence estimates for 2010 from cancer registry data and relative risk estimates from published meta-analyses. Three counterfactual scenarios were evaluated: reducing BMI to maximally 21 kg/m² (main analysis) and weight reductions among overweight and obese persons of 5% and 10%...
October 17, 2018: Obesity Facts
Dantong Sun, Helei Hou, Chuantao Zhang, Xiaochun Zhang
Background and purpose: Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2. Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different doses of drugs, and different incidences of adverse events (AEs), which has resulted in a lack of accurate measurement of the efficacy and safety of apatinib. Thus, we performed this meta-analysis to evaluate the efficacy and safety of apatinib...
2018: OncoTargets and Therapy
N Namazi, B Larijani, L Azadbakht
OBJECTIVE: Although many risk factors for cancers have been well defined, the effects of dietary inflammation have remained controversial. We aimed to summarize the association between the dietary inflammatory index (DII) and the risk of cancer. STUDY DESIGN: A systematic review and meta-analysis on prospective studies. METHODS: Electronic databases including PubMed/MEDLINE, Scopus, and Web of Science were searched to find relevant articles published in English up to February 2017...
October 12, 2018: Public Health
Kai-Teng Cai, Cai-Xia Feng, Jin-Che Zhao, Rong-Quan He, Jie Ma, Jin-Cai Zhong
Breast cancer (BC) has been identified as the leading malignancy in women worldwide. However, the potential molecular mechanism of microRNA (miR)‑203a‑3p in BC remains to be elucidated. The present study evaluated the expression of miR‑203a‑3p in BC and adjacent normal tissue in several publically available datasets. The distinguishability of precursor miR‑203a and miR‑203a‑3p in BC tissue and adjacent breast tissue was assessed using receiver operating characteristic (ROC) and summarized ROC (sROC) approaches...
October 10, 2018: Molecular Medicine Reports
Raffaele Frazzi
Mammalian silent information regulator 1 (SIRT1) is reported to play a role in cancers of the secretory organs, including thyroid, pancreatic endocrine, and ovarian tumors [1, 2, 3, 4]. A recent meta-analysis conducted on 37 selected studies of human cancers analyzed the correlations of overall survival (OS), disease-free survival (DFS) and relapse-free survival (RFS) with SIRT1 expression [5]. This study reported that SIRT1 overexpression was associated with a worse OS in liver and lung cancers, while it was not correlated with OS in breast cancer, colorectal cancer, or gastric carcinoma...
2018: Frontiers in Endocrinology
Alessandro Inno, Sandro Barni, Antonio Ghidini, Alberto Zaniboni, Fausto Petrelli
INTRODUCTION: One year is the standard duration of adjuvant trastuzumab for human epidermal receptor-2 (HER2) positive (HER2+) breast cancer (BC). Indeed, a shorter duration of trastuzumab can reduce cardiotoxicity and the costs involved and could provide the same benefit as a one-year treatment. We evaluated the available evidence from randomised controlled trials (RCTs) by comparing 1 year versus a shorter duration of adjuvant trastuzumab for HER2+ BC. PATIENTS AND METHODS: A systematic search of PubMed, EMBASE, The Cochrane Library and conference proceedings was carried out in order to identify the RCTs that investigated a standard versus a shorter duration of adjuvant trastuzumab in HER2+ BC patients...
October 13, 2018: Breast Cancer Research and Treatment
Yong Hong Liu, Ling Bo Xue, Yan Fang Yang, Tian Jiao Zhao, Yang Bai, Bu Yong Zhang, Jie Li
BACKGROUND: This study aimed to investigate the potential of diffuse optical spectroscopy (DOT) for monitoring the responses of patients with breast cancer to neoadjuvant chemotherapy (NAC). METHODS: We searched PubMed, EMBASE, Cochrane Database of Systematic Reviews, and Web of Science for relevant studies. Data were extracted for pooled analysis, heterogeneity testing, threshold effect testing, sensitivity analysis, publication bias analysis, and subgroup analysis...
October 2018: Medicine (Baltimore)
Janine M Simons, Thiemo J A van Nijnatten, Carmen C van der Pol, Ernest J T Luiten, Linetta B Koppert, Marjolein L Smidt
OBJECTIVE: The aim of this study was to perform a systematic review and meta-analysis to assess the accuracy of different surgical axillary staging procedures compared with ALND. SUMMARY OF BACKGROUND DATA: Optimal axillary staging after neoadjuvant systemic therapy (NST) in node-positive breast cancer is an area of controversy. Several less invasive procedures, such as sentinel lymph node biopsy (SLNB), marking axillary lymph node with radioactive iodine seed (MARI), and targeted axillary dissection (a combination of SLNB and a MARI-like procedure), have been proposed to replace the conventional axillary lymph node dissection (ALND) with its concomitant morbidity...
October 11, 2018: Annals of Surgery
S R Tee, L A Devane, D Evoy, J Rothwell, J Geraghty, R S Prichard, E W McDermott
BACKGROUND: Neoadjuvant chemotherapy for breast cancer has the potential to achieve a pathological complete response in up to 40 per cent of patients, converting disease that was initially node-positive to node-negative. This has raised the question of whether sentinel lymph node biopsy could be an alternative to axillary lymph node dissection in these patients. The aim was to undertake a systematic review and meta-analysis of the accuracy and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer...
November 2018: British Journal of Surgery
Yu-Tuan Wu, Zhou Xu, Ke Zhang, Jiu-Song Wu, Xin Li, Bilal Arshad, Ying-Cun Li, Zhong-Liang Wang, Hong-Yuan Li, Kai-Nan Wu, Ling-Quan Kong
The concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy (NAC) has been proposed to improve the pathologic complete response (pCR) rate, although there are conflicting views about its efficacy and safety. The purpose of this study was to evaluate the efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based NAC for human epidermal growth factor receptor 2 (HER2)-positive locally advanced breast cancer. We systematically searched PubMed, Embase, and Cochrane databases from inception until July 1, 2017, for relevant articles...
2018: Therapeutics and Clinical Risk Management
Nazli Namazi, Pardis Irandoost, Javad Heshmati, Bagher Larijani, Leila Azadbakht
BACKGROUND & AIMS: Several cohort and case-control studies examined the association between fat mass (FM) and the risk of breast cancer; however, findings are conflicting. The purpose of the present study was to systematically review this association and conducted a meta-analysis, if possible. METHOD: A systematic search of PubMed/Medline, Scopus, Web of Science and Embase databases was conducted for cohort and case-control studies, between January 2000 and 31 March 2018 with no language limitations...
September 19, 2018: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
Leimarembi Devi Naorem, Mathavan Muthaiyan, Amouda Venkatesan
Triple-negative breast cancer (TNBC) has attracted more attention compared with other breast cancer subtypes due to its aggressive nature, poor prognosis, and chemotherapy remains the mainstay of treatment with no other approved targeted therapy. Therefore, the study aimed to discover more promising therapeutic targets and investigating new insights of biological mechanism of TNBC. Six microarray data sets consisting of 463 non-TNBC and 405 TNBC samples were mined from Gene Expression Omnibus. The data sets were integrated by meta-analysis and identified 1075 differentially expressed genes...
October 9, 2018: Journal of Cellular Biochemistry
Anthony Matthews, Susannah Stanway, Ruth E Farmer, Helen Strongman, Sara Thomas, Alexander R Lyon, Liam Smeeth, Krishnan Bhaskaran
OBJECTIVE: To investigate the effect of endocrine therapies on a wide range of specific clinical cardiovascular disease outcomes in women with a history of non-metastatic breast cancer. DESIGN: Systematic review and meta-analysis of randomised controlled trials and observational studies. DATA SOURCES: Medline and Embase up until June 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Studies were included if they investigated the risk of a specific cardiovascular disease outcome associated with use of either tamoxifen or an aromatase inhibitor, or compared the two treatments, in women with a history of non-metastatic breast cancer...
October 8, 2018: BMJ: British Medical Journal
Chun-Yi Lin, Cheng-Li Lin, Chia-Hung Kao
PURPOSE: This systematic review and meta-analysis was performed to assess the staging/restaging performance of F18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in breast cancer. METHODS: A comprehensive search was performed in PubMed databases for studies reporting the staging performance of F18-FDG PET/MRI in breast cancer from the inception of these databases to January 29, 2018. Eight studies were included in this systematic review and meta-analysis...
October 2018: European Journal of Radiology
Wenjie Xia, Wuzhen Chen, Jiangfeng Tu, Chao Ni, Kexin Meng
BACKGROUND The association between platelet distribution width (PDW) and cancer has been evaluated by a few studies, but the influence of PDW on cancer prognosis is unclear. Therefore, we conducted the present meta-analysis. MATERIAL AND METHODS We identified relevant research using identical search strategies. The influence of PDW level on cancer prognosis, as well as clinical characteristics, was analyzed. RESULTS A total of 11 studies comprising 2625 cancer patients were included in our meta-analysis. The results suggested that high PDW level was obviously related to poor OS (HR=1...
October 6, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
Peng-Fei Wang, Si-Ying Song, Ting-Jian Wang, Wen-Jun Ji, Shou-Wei Li, Ning Liu, Chang-Xiang Yan
Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor progression, mainly through immune suppression. Inverse correlations have been observed between MDSC levels and patient survival for various malignancies. The purpose of this meta-analysis was to evaluate the prognostic value of pretreatment circulating MDSCs. We searched MEDLINE and EMBASE from their inceptions to September 2017 to identify relevant articles. Using a fixed or random effects model, pooled hazard ratios (HRs) were estimated for overall survival (OS) and combined disease-free survival, progression-free survival, and recurrence-free survival (DFS/PFS/RFS)...
2018: Oncoimmunology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"